Clinical trials: Neurocognitive Development
Alzheimer Disease
Enhancing Consent for Alzheimer's Research
The purpose of this study is to evaluate the efficacy of an enhanced consent procedure for patients with mild-to-moderate Alzheimer disease, and to identify factors and patient characteristics that predict the degree to which…
- Trial name
- BWP-AD (NCT00453544)
- Testing
- Enhanced Consent Procedure, Routine Consent Procedure
- Where
- United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
APOE 4
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development
The purpose of this project is to test the hypothesis that AGB101 low dose levetiracetam extended release formulation can reduce abnormal hyperfunctional activity in the hippocampus in normal, healthy adults.
- Trial name
- NCT03461861
- Testing
- AGB101 220 mg
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Mild Cognitive Impairment, Healthy Aging
SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting
The goal of this study is to test efficacy and safety of person-centered, culturally-informed protocols for disclosure of different combinations of Alzheimer's dementia risk factors.
- Trial name
- SHARE(D) (NCT04309500)
- Testing
- Personalized DAT Risk Disclosure Protocol
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Alzheimer's Disease
Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study
The purpose of this study is to evaluate the safety of administration and effects of valproic acid on clusterin expression in cognitively-intact, healthy, elderly subjects.
- Trial name
- VPA (NCT01729598)
- Testing
- Valproic Acid
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Gregory Jicha, 323-5550